Home /
Future Studies
At Equipo Ciencia we continue to promote new clinical studies to advance in the prevention and treatment of different diseases. These projects will allow us to generate quality scientific evidence, always with the commitment to care for each participant and contribute to the welfare of the community.
Learn about our future studies and, if you want to join us as a volunteer, fill out the form to be part of our next research.
Following the research study that demonstrated the efficacy of the vaccine RSVpreF vaccine, which is given in the last months of pregnancy and protects infants from contracting severe respiratory RSV infection in the first months of life, Equipo Ciencia was selected to carry out a new stage of this work.
Our research center will conduct a new study that will evaluate the safety and immune response of a second dose of the vaccine in women in a new pregnancy and will study the duration of vaccine protection among women who received a single dose. A requirement for participation in this study is to have received a dose of RSV vaccine in a previous pregnancy.
RECRUITMENT OPENING SOON
A new treatment for patients with bronchiectasis
Equipo Ciencia will carry out a study that will evaluate the efficacy, safety and tolerability of a new drug in people with bronchiectasis. .
This chronic lung disease is characterized by an abnormal and irreversible dilatation of the airways that hinders the proper elimination of mucus, causes chronic fatigue, and leads to recurrent lung infections.
The objective of this study is to identify whether this new treatment delays the progression of the disease, which would allow an improvement in the quality of life of those affected.
RECRUITMENT OPENING SOON
New study against COVID-19 for people at risk of severe disease
Once again, Equipo Ciencia will conduct a research study focusing on SARS-CoV-2 virus infection and its complications.
In this opportunity, the protocol will evaluate the efficacy and safety of a drug administered in adolescent and adult participants with confirmed COVID-19 who, due to pre-existing diseases, are at high risk of developing severe disease.
RECRUITMENT OPENING SOON
Study against COVID-19 for people with severe immunocompromise
Although SARS-CoV-2 vaccines have proven to be effective in preventing severe disease in healthy individuals, there are specific populations that require further research. Team Science will conduct a clinical trial in adults over 18 years of age, which will evaluate the efficacy and safety of a drug intended for patients with confirmed COVID-19 who are severely immunocompromised and who, precisely because of this condition, are at high risk of developing severe disease.
RECRUITMENT OPENING SOON
Clostridium difficile: a hidden threat behind antibiotic use
Our center has been selected to evaluate a vaccine against clostridium difficile, a bacterium that can cause serious intestinal infections, especially in older adults or people with pre-existing diseases such as COPD, heart disease, liver disease or chronic kidney disease.
This infection tends to occur more frequently in people with regular contact with the healthcare system (due to surgery, hospitalization or medical treatment) and can cause anything from mild diarrhea to more serious conditions.
Many antibiotics alter the balance between the types and quantity of bacteria living in the intestine. In this imbalance, some disease-causing bacteria can develop and replace the harmless (or even beneficial) bacteria living in the intestine, causing inflammation, increased permeability of the intestinal barrier and diarrhea.
Because clostridium difficile is becoming more and more frequent, a research study will be conducted to evaluate the efficacy, safety and tolerability of a vaccine against this bacterium, to be administered in 2 doses, with a 6-month interval between the first and the second.
RECRUITMENT OPENING SOON
